Factors Associated With Recurrent Venous Thromboembolism During Extended Apixaban Therapy for Cancer-Associated Thrombosis
Year: 2026
Type: article
Abstract: A lthough the API-CAT (APIxaban Cancer Asso- ciated Thrombosis) trial demonstrated the noninferiority and safety of reduced-dose apixaban (2.5 mg twice daily) compared with standard full-dose (5 mg twice daily) for patients who completed at least 6 months of anticoagulant therapy to evaluate extended treatment for cancer-associated thrombosis (CAT), recurrent venous thromboembolism (VTE) still occurred in 2.5% of patients (42 of 1,766). 1 Recurrent VTE during the extended anticoagulant treatment period represents treatment failure and remains a clinical concern in CAT associated with substantial morbidity, impaired quality of life, hospitalizations, and increased mortality.[2][3][4] Although several factors associated with recurrent VTE have been identified during the first 6 months after the index event, the determinants of recurrence beyond this period remain poorly characterized.In this ancillary analysis of the API-CAT randomized double-blind trial (NCT03692065), we evaluated 1,766 adults with active cancer who completed at least 6 months of anticoagulation and received extended apixaban for an additional 12 months.1,4 Eligible patients had no objectively documented symptomatic recurrent VTE at study entry.Primary outcome was centrally adjudicated recurrent VTE during the 12-month follow-up, defined as a composite of recurrent symptomatic VTE, incidental proximal deep vein thrombosis or pulmonary embolism, or VTE-related death.The Comité de Protection des Personnes Ile de France II provided ethics approval (2018-05-01 RIPH 1).To prevent model over-
Source: JACC CardioOncology
Institutions: Inserm, Université Paris Cité, Hôpital Louis-Mourier, Assistance Publique – Hôpitaux de Paris, Paris Cardiovascular Research Center, University of Geneva, University Hospital of Geneva, University of Ottawa, Ottawa Hospital Research Institute, Leiden University Medical Center, University of Perugia, Pitié-Salpêtrière Hospital, Centre Hospitalier Universitaire Amiens-Picardie, Hôpital Foch, Université de Bretagne Occidentale, Centre Hospitalier Régional Universitaire de Brest, Mines Saint-Étienne, Centre Hospitalier Universitaire de Saint-Étienne, Centre d'Investigation Clinique - Epidémiologie Clinique Saint-Etienne, SAnté INgenierie BIOlogie Saint-Etienne, Université Jean Monnet
Language: English
Subfield: Internal Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $4,200
OpenAlex ID: W7222714780